Sertraline oral concentrate
AssigneePfizer Inc.
InventorsNancy J. Harper, Gautam R. Ranade, Willard M. Welch
Life of this patent
Estimating the term…
Abstract
The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
Claims12
A pharmaceutical composition which comprises:
- an essentially nonaqueous, liquid concentrate solution for oral administration comprising an amount of sertraline or a pharmaceutically acceptable salt thereof and one or more essentially nonaqueous pharmaceutically acceptable excipients;
- wherein at least one of the excipients is liquid, and wherein the excipients are selected from the group consisting of ethanol, glycerin, polyethylene glycol and propylene glycols, and wherein the concentrate comprises sertraline in an amount of about 1 to about 88 mg/ml.
The compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
Dependencies are inferred from the claim text.